Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

recruiting133%
unknown267%

Recent Activity

1 active trials
Showing 3 of 3
unknownnot_applicable

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT04916860
recruitingnot_applicable

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

NCT05626400
unknownnot_applicable

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

NCT04928105

Clinical Trials (3)

Showing 3 of 3 trials
NCT04916860Not Applicable

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Unknown
NCT05626400Not Applicable

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting
NCT04928105Not Applicable

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3